FuelNation Inc., a development stage company, engages in the purchase, transportation, storage, and resale of petroleum products. The company is headquartered in West Palm Beach, Florida.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-17.47M |
| EBITDA | $-48.71M |
| Operating Margin | 0.00% |
| Return on Equity | -79.60% |
| Return on Assets | -24.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.41 |
| Price-to-Book | 0.64 |
| Price-to-Sales (TTM) | 2.54 |
| EV/Revenue | 1.333 |
| EV/EBITDA | 2.08 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $48.31M |
| Float | $47.32M |
| % Insiders | 2.05% |
| % Institutions | 28.55% |
AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.
AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it delivered a scientific presentation at Eilat XVIII (the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices) in Madrid, Spain. The presentation outlined the biological rationale underlying the Company's clinical development program evaluating simufilam in TSC-related epilepsy.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FLNA and any ticker you trade — then tracks every position and per-strategy win rate.
